CEL-SCI Co. (NYSE:CVM - Free Report) - Zacks Small Cap issued their Q2 2024 earnings estimates for shares of CEL-SCI in a note issued to investors on Monday, April 15th. Zacks Small Cap analyst J. Vandermosten forecasts that the company will earn ($0.14) per share for the quarter. The consensus estimate for CEL-SCI's current full-year earnings is ($0.48) per share. Zacks Small Cap also issued estimates for CEL-SCI's Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.11) EPS and FY2026 earnings at ($0.24) EPS.
Separately, StockNews.com downgraded shares of CEL-SCI from a "hold" rating to a "sell" rating in a report on Friday, March 15th.
Read Our Latest Stock Analysis on CVM
CEL-SCI Price Performance
Shares of NYSE CVM traded down $0.07 during mid-day trading on Tuesday, reaching $1.52. 171,172 shares of the company were exchanged, compared to its average volume of 305,750. CEL-SCI has a 52 week low of $1.04 and a 52 week high of $3.23. The company has a quick ratio of 0.78, a current ratio of 1.26 and a debt-to-equity ratio of 0.75. The stock has a market capitalization of $82.05 million, a PE ratio of -2.24 and a beta of 1.29. The company's 50 day moving average price is $2.06 and its 200 day moving average price is $2.18.
CEL-SCI (NYSE:CVM - Get Free Report) last posted its quarterly earnings data on Wednesday, February 14th. The company reported ($0.14) EPS for the quarter.
Hedge Funds Weigh In On CEL-SCI
A number of large investors have recently added to or reduced their stakes in CVM. Renaissance Technologies LLC purchased a new position in CEL-SCI in the 1st quarter worth $3,037,000. Millennium Management LLC increased its position in shares of CEL-SCI by 212.6% in the second quarter. Millennium Management LLC now owns 572,700 shares of the company's stock valued at $2,577,000 after acquiring an additional 389,513 shares during the period. Goldman Sachs Group Inc. increased its position in shares of CEL-SCI by 400.6% in the first quarter. Goldman Sachs Group Inc. now owns 343,458 shares of the company's stock valued at $1,350,000 after acquiring an additional 274,854 shares during the period. D.A. Davidson & CO. increased its position in shares of CEL-SCI by 564.2% in the fourth quarter. D.A. Davidson & CO. now owns 290,928 shares of the company's stock valued at $791,000 after acquiring an additional 247,128 shares during the period. Finally, Walleye Capital LLC increased its position in shares of CEL-SCI by 353.3% in the first quarter. Walleye Capital LLC now owns 277,278 shares of the company's stock valued at $1,090,000 after acquiring an additional 216,113 shares during the period. Hedge funds and other institutional investors own 12.08% of the company's stock.
CEL-SCI Company Profile
(
Get Free Report)
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.
Featured Articles
Before you consider CEL-SCI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CEL-SCI wasn't on the list.
While CEL-SCI currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
